Pilot Study of Fisetin to Reduce Senescent Cells and Improve Walking in People Aged 50 and Older with Peripheral Artery Disease

What this Trial Is About

Researchers are conducting a pilot randomized trial to study whether Fisetin, a natural flavanol found in fruits like strawberries and apples, can reduce the number of aging cells senescent cells in blood, muscle, and fat tissues of people with peripheral artery disease PAD. The study also aims to see if reducing these cells improves walking ability measured by the six-minute walk test. Additionally, the trial will explore if Fisetin lowers inflammation markers such as interleukin-6 and other senescence-related markers. Participants aged 50 and older with PAD will be randomly assigned to receive either Fisetin or a placebo. The treatment involves taking Fisetin or placebo capsules at a dose of 20 mg per kg of body weight once daily for two days, followed by 12 days without treatment, repeated over a four-month period. The capsules are provided in 100 mg tablets, with dosing rounded to the nearest 100 mg. During the study, participants will undergo assessments at the start and after four months, including tests of walking distance, hand grip strength, physical performance, muscle blood flow, and cell markers of aging. Researchers will monitor these measures to evaluate changes and safety throughout the trial period. The total study duration for each participant is four months, during which their health and response to the treatment will be closely followed.

Fisetin to Reduce Senescence and Mobility Impairment in PAD